SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q/A

             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

(X)      Quarterly report for the quarterly period ended December 31, 1997

                                       OR

(   )    Transition Report Pursuant to Section 13 or 15(d) of The Securities
         Exchange Act of 1934

Commission file number 1-9601

                           K-V PHARMACEUTICAL COMPANY
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         DELAWARE                                        43-0618919
(State or other jurisdiction of             (I.R.S. Employer Identification No.)
 incorporation or organization)

                2503 SOUTH HANLEY ROAD, ST. LOUIS, MISSOURI 63144
--------------------------------------------------------------------------------
                    (Address or principal executive offices)
                                   (Zip Code)

                                 (314) 645-6600
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------
              (Former name, former address and former fiscal year,
                         if changed since last report)

         Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934 during the preceding 12 months (or such shorter  period that the registrant
was  required  to file such  reports)  and (2) has been  subject to such  filing
requirements for the past 90 days.

Yes  X            No

         Title of Class of                           Number of Shares
         Common Stock                       Outstanding as of this Report Date

Class A Common Stock, par value $.01 per share                       7,774,177
                                                              ------------------
Class B Common Stock, par value $.01 per share                       4,296,150
                                                              ------------------
<PAGE>

Item 6: Exhibits and Reports on Form 8-K. 

         (a)  Exhibits

              Exhibit 27.

         (b) The Company did not file any reports on Form 8-K during the quarter
ended December 31, 1997.

<PAGE>
                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                               KV PHARMACEUTICAL COMPANY



Date:    February  17,  1998                  /s/ Marc S. Hermelin
         ---------------------------          --------------------
                                              Marc S. Hermelin
                                              Vice Chairman of the Board




Date:    February  17,  1998                 /s/ Gerald R. Mitchell
     -------------------------------         ----------------------
                                             Gerald R. Mitchell
                                             Vice President - Finance
                                             Chief Financial Officer